Scalp Hair Loss in Women: Labs, Causes, and Next Steps

Why Women Lose Scalp Hair Differently Than Men

Hair loss is not a single disease. In women, the pattern, the pace, and the hormonal drivers differ substantially from what happens in men, and the evidence base for female-specific treatment has only recently started to catch up. Female-pattern hair loss (FPHL) produces diffuse thinning over the crown and mid-scalp with preservation of the frontal hairline, while male-pattern loss typically starts at the temples and vertex. That distinction matters clinically because it changes both how you investigate the cause and which treatments are appropriate.

The Hair Cycle and Why Women Are Vulnerable

Each hair follicle cycles through three phases: anagen (active growth, lasting 2-6 years), catagen (transition, roughly 2 weeks), and telogen (resting and shedding, roughly 3 months). At any moment, about 85-90% of scalp follicles are in anagen. Anything that abruptly shortens anagen or pushes follicles into telogen simultaneously produces the large-scale shedding called telogen effluvium.

Women experience more physiological triggers for this cycle disruption: pregnancy, delivery, stopping hormonal contraception, crash dieting, and the estrogen withdrawal of perimenopause. Estrogen prolongs anagen, so when estrogen falls, follicles cycle faster and shed more.

Sex-Specific Physiology You Need to Know

Androgens, specifically dihydrotestosterone (DHT), bind androgen receptors in the dermal papilla and gradually miniaturize susceptible follicles. Women produce androgens too, primarily in the ovaries and adrenal glands. Women with PCOS, adrenal hyperplasia, or androgen-secreting tumors produce more. Even women with normal total androgen levels may have follicles that are hypersensitive to DHT. A 2020 review in the Journal of the American Academy of Dermatology confirmed that androgen receptor polymorphisms explain why some women thin even with normal serum androgens.

What Causes Scalp Hair Loss in Women? A Life-Stage Map

The cause of your hair loss depends heavily on where you are in your reproductive life.

Reproductive Years (Ages ~18-45)

The most common causes during the reproductive years are:

• Telogen effluvium triggered by a stressor 2-4 months prior (illness, surgery, rapid weight loss, iron depletion, or starting/stopping hormonal contraception)
• PCOS-related androgen excess, which affects roughly 8-13% of women of reproductive age and often presents with scalp thinning alongside hirsutism and irregular cycles
• Iron deficiency without frank anemia, the most under-recognized and reversible cause
• Thyroid dysfunction, both hypothyroidism and hyperthyroidism
• Early FPHL, which can begin in the late 20s or early 30s even without measurable androgen excess

Hormonal contraceptives with high androgenic progestins (such as norethindrone or levonorgestrel) may worsen hair loss in susceptible women, while low-androgenic or anti-androgenic pills (such as drospirenone or norgestimate) may improve it. ACOG guidance on combined oral contraceptives does not list hair loss as a contraindication but acknowledges progestin androgenicity as clinically relevant.

Postpartum and Lactation

Postpartum hair shedding, called postpartum telogen effluvium, is nearly universal. During pregnancy, elevated estrogen extends the anagen phase and you lose less hair than normal. After delivery, estrogen drops sharply and those retained follicles enter telogen simultaneously. Shedding peaks between 3 and 4 months postpartum and typically resolves by 6-12 months without treatment.

If shedding is severe or persists beyond 12 months, check ferritin (iron stores drop dramatically with breastfeeding), thyroid function, and zinc. Minoxidil, the most widely used topical hair-loss treatment, transfers into breast milk and should not be used during breastfeeding until safety data in lactating women are available. Oral minoxidil carries the same caution.

Trying to Conceive (TTC)

Women using finasteride or dutasteride for hair loss must stop these medications well before attempting conception. Both are potent 5-alpha reductase inhibitors classified as FDA Category X in pregnancy due to the risk of feminization of a male fetus. The FDA prescribing information for finasteride states that women who are or may become pregnant should not handle crushed or broken tablets.

If you are actively trying to conceive and want to continue some form of treatment, discuss low-level laser therapy (LLLT) or platelet-rich plasma (PRP) with your provider. Neither carries a teratogenic classification, though controlled data in pregnancy are thin.

Perimenopause (Typically Ages 45-55)

Estrogen decline during perimenopause removes the follicle-protective effect of estrogen and relatively amplifies the effect of circulating androgens. This is why many women notice diffuse thinning for the first time in their mid-40s even when androgen levels look "normal." A cross-sectional study in Menopause found that FPHL severity correlated with menopausal status independent of serum androgen levels.

Menopausal hormone therapy (MHT) with estrogen may slow FPHL progression, though randomized trial data specifically for hair outcomes remain limited. The Menopause Society (formerly NAMS) does not list hair retention as a primary indication for MHT, but does not discourage its consideration in women who also have other menopause symptoms. Progestin choice matters: micronized progesterone is preferred over synthetic progestins with androgenic activity in women with FPHL.

Post-Menopause

Post-menopausal women with new or worsening scalp thinning should be evaluated for late-onset androgen excess (which can signal adrenal or ovarian pathology), secondary causes such as hypothyroidism, and nutritional deficiencies common in older women (B12, ferritin, zinc, vitamin D). Topical minoxidil 2% or 5% remains the first-line pharmacological option at this stage.

The Diagnostic Work-Up: Which Labs Should You Get?

The right blood panel narrows the differential rapidly. Most dermatologists and gynecologists use a core set, then add targeted tests based on your history.

Core Lab Panel

| Test | What It Tells You | Target Range for Hair Health | |---|---|---| | Ferritin | Iron stores | Many hair specialists target >70 ng/mL, not just the lab "normal" of >12 | | TSH (with free T4 if abnormal) | Thyroid function | 0.5-2.5 mIU/L optimal for many women | | Complete blood count (CBC) | Rules out anemia | Hemoglobin >12 g/dL in women | | Total and free testosterone | Androgen status | Free testosterone most sensitive for excess | | DHEA-S | Adrenal androgen source | Elevated suggests adrenal contribution | | Prolactin | Pituitary function | Hyperprolactinemia disrupts the HPO axis |

When to Add Extended Testing

If your core panel is normal but shedding continues, your clinician may add:

• Sex hormone binding globulin (SHBG): Low SHBG raises bioavailable androgens even when total testosterone looks normal. Women with insulin resistance (including PCOS) often have suppressed SHBG.
• Fasting insulin and glucose: Insulin resistance amplifies ovarian androgen production.
• Zinc and vitamin D: Deficiencies are common and correctible.
• 17-hydroxyprogesterone: Screens for non-classic congenital adrenal hyperplasia, which mimics PCOS and causes hair loss.
• Antinuclear antibody (ANA) and anti-double-stranded DNA: If the pattern suggests a scarring alopecia or lupus-related hair loss.

Ferritin: The Most Commonly Missed Finding

Standard lab reference ranges mark ferritin as "normal" above 12-15 ng/mL. Hair follicles, however, are highly metabolically active and sensitive to iron availability. A study published in the Journal of Investigative Dermatology found that women with telogen effluvium had significantly lower ferritin levels than controls, with the strongest association below 41 ng/mL. Many hair-specialist clinicians, including the authors of a 2017 review in Skin Appendage Disorders, recommend targeting ferritin at 70 ng/mL or above before concluding that iron is not a factor.

Ask your clinician specifically for ferritin, not just a standard iron panel or CBC. Anemia can be absent while stores are already depleted enough to affect hair.

Dermoscopy: The Clinical Exam That Changes Everything

A hand-held dermatoscope lets a trained clinician see follicle miniaturization, perifollicular scaling, and vascular changes that are invisible to the naked eye. Dermoscopic criteria for FPHL include hair shaft diameter variability greater than 20% and an increased proportion of vellus hairs. This exam takes about five minutes in the office and can spare you from an unnecessary scalp biopsy.

Scalp biopsy is reserved for cases where the pattern is atypical, where scarring alopecia (lichen planopilaris, frontal fibrosing alopecia) is suspected, or when treatment response is absent after 12 months.

Diagnosing the Specific Type of Hair Loss

Getting the right diagnosis before starting treatment is the step most women skip. Treatment for FPHL differs from treatment for alopecia areata, which differs from treatment for telogen effluvium driven by iron deficiency. Starting minoxidil for what turns out to be a correctable thyroid problem delays resolution by months.

Female-Pattern Hair Loss (Androgenetic Alopecia)

FPHL is graded using the Ludwig scale (I, II, or III, reflecting severity of crown thinning) or the Sinclair scale. It is the most common form of hair loss in women and, because it is progressive, earlier treatment produces better outcomes. Topical minoxidil 5% foam once daily is FDA-approved for FPHL and is considered first-line pharmacological treatment.

Alopecia Areata

Alopecia areata is an autoimmune condition producing discrete, round patches of hair loss. Women develop it at roughly the same rate as men. The presence of exclamation-mark hairs at the patch periphery on dermoscopy is diagnostic. Baricitinib (Olumiant), a JAK1/2 inhibitor, became the first FDA-approved systemic treatment for severe alopecia areata in 2022 and is approved for adults of any sex. It carries a contraindication in pregnancy and requires reliable contraception during use.

Telogen Effluvium

Telogen effluvium resolves when the trigger is removed and any deficiency is corrected. The pull test, where a clinician gently pulls 40-60 hairs from multiple scalp regions, yields more than 6 telogen hairs (club-shaped roots) in active effluvium. Reassurance and correction of the underlying cause are the primary interventions. Minoxidil may shorten duration if telogen effluvium is overlapping with early FPHL.

Scarring Alopecias

Frontal fibrosing alopecia (FFA) is increasing in incidence and disproportionately affects post-menopausal women. It produces a band-like recession of the frontal and temporal hairline with perifollicular erythema. Once scarring occurs, regrowth is not possible, making early diagnosis and treatment with 5-alpha reductase inhibitors or hydroxychloroquine critical to halting progression. A 2023 systematic review in JAMA Dermatology noted the rising prevalence of FFA and the lack of randomized trial data to guide treatment.

Treatment Options by Life Stage and Cause

The table below presents a practical framework for matching treatment to cause and life stage. No published guideline has organized options this way for a female-only readership.

| Cause | Reproductive Years | Postpartum / Lactating | Peri/Post-menopause | |---|---|---|---| | FPHL | Topical minoxidil 5%, anti-androgenic OCP, spironolactone | Topical minoxidil (hold if breastfeeding), treat deficiencies | Topical or oral minoxidil, spironolactone, consider MHT | | Telogen effluvium | Correct trigger (iron, thyroid, crash diet) | Replete ferritin, zinc; watchful waiting | Correct deficiency; consider LLLT | | PCOS-related | Spironolactone 50-200 mg/day, anti-androgenic OCP | Spironolactone contraindicated in breastfeeding | Spironolactone, topical minoxidil | | Alopecia areata | Intralesional corticosteroids, baricitinib (with contraception) | Limited data; avoid JAK inhibitors | Baricitinib, dupilumab off-label | | FFA | Hydroxychloroquine, finasteride (with contraception) | Avoid finasteride; hydroxychloroquine limited data | 5-ARI, hydroxychloroquine | | Iron deficiency | Oral iron to ferritin >70 ng/mL | Oral iron (safe in lactation) | Oral iron, investigate cause of deficiency |

Spironolactone: A Women's-Health Workhorse

Spironolactone, an aldosterone antagonist with anti-androgenic properties, is one of the most frequently prescribed off-label treatments for FPHL and PCOS-related hair loss in women. Doses used for hair loss range from 50 to 200 mg daily, typically starting at 50 mg and titrating based on response and tolerability. It is contraindicated in pregnancy because it feminizes male fetuses. Women of reproductive age using spironolactone need reliable contraception.

Spironolactone also causes menstrual irregularity in some women, particularly at higher doses. Combining it with an oral contraceptive both manages contraception and reduces cycle disruption.

Oral Minoxidil: Low-Dose Data in Women

Low-dose oral minoxidil (0.25-2.5 mg daily) has attracted significant attention for FPHL. A randomized trial published in the Journal of the American Academy of Dermatology in 2020 found that 1 mg oral minoxidil daily was non-inferior to 5% topical minoxidil for FPHL with a favorable side-effect profile. The most common side effects in women were mild facial hypertrichosis and fluid retention. Oral minoxidil is not FDA-approved for hair loss; prescribing is off-label. It is not recommended in pregnancy or breastfeeding given cardiovascular effects and lack of safety data in these populations.

What About Finasteride and Dutasteride in Women?

Finasteride 1 mg daily is FDA-approved only for men with androgenetic alopecia. In post-menopausal women, off-label use of finasteride has shown benefit in small trials. A double-blind randomized trial in post-menopausal women found 1 mg finasteride daily produced modest but statistically significant improvements in hair density at 12 months. In pre-menopausal women, use requires highly reliable contraception because of Category X teratogenicity. Dutasteride carries the same teratogenic risk.

When Should You Worry About Scalp Hair Loss?

Most hair shedding in women is benign, but certain features warrant prompt evaluation.

See your clinician within 2-4 weeks if you notice:

• Diffuse shedding of more than 150-200 hairs per day persisting beyond 8 weeks
• Scalp pain, burning, or tenderness (possible scarring alopecia)
• Patchy loss with smooth, completely bald areas (possible alopecia areata)
• Recession of the frontal hairline with loss of eyebrows (possible FFA)
• Hair loss alongside significant fatigue, weight change, or menstrual irregularity (thyroid, PCOS, or adrenal disease)
• Any rapid or sudden total scalp shedding (possible acute telogen effluvium from serious illness)

The American Academy of Dermatology identifies hair thinning accompanied by menstrual changes, acne, or hirsutism as a cluster that should prompt androgen excess evaluation, not a dermatology-only work-up.

Who This Is Right For (and Who Needs a Different Approach)

Good candidates for standard FPHL treatment

• Women with a family history of hair thinning on either parent's side
• Gradual onset, symmetric crown and mid-scalp thinning, no scalp symptoms
• Normal or mildly elevated androgens, correctable deficiencies

Women who need specialist referral first

• Suspected scarring alopecia (FFA, lichen planopilaris): refer to dermatology promptly, as damage is irreversible
• Confirmed or suspected PCOS with metabolic features: co-management with reproductive endocrinology or gynecology
• Alopecia areata affecting more than 50% of the scalp: dermatology for JAK inhibitor evaluation
• Hair loss with systemic symptoms suggesting lupus, adrenal tumor, or pituitary pathology: internal medicine or endocrinology

Special considerations by life stage

Perimenopausal women with FPHL have the broadest toolkit: MHT may address both vasomotor symptoms and FPHL simultaneously, spironolactone addresses androgens, and topical minoxidil addresses the follicle directly. A trial of all three simultaneously is reasonable in women with moderate to severe FPHL in perimenopause, though evidence for the combination specifically is drawn from case series rather than randomized trials. That evidence gap is real, and your clinician should say so.

Pregnancy, Lactation, and Contraception: The Non-Negotiables

This section applies to every woman of reproductive potential considering pharmacological hair-loss treatment.

Finasteride and dutasteride are Category X. Stop at least one month before attempting conception. Because these drugs are present in semen of treated men, the FDA warning extends to handling crushed tablets during pregnancy. For women taking these drugs, a barrier method alone is insufficient; use a highly effective method such as an IUD, implant, or tubal ligation while on treatment.

Spironolactone is contraindicated in pregnancy due to anti-androgenic effects on fetal development. Use in combination with hormonal contraception is standard practice for pre-menopausal women.

Minoxidil (topical and oral) is FDA Pregnancy Category C. Animal data show adverse effects at high doses; human data are insufficient. The general recommendation is to stop minoxidil before attempting conception and avoid use during pregnancy and breastfeeding. The FDA label for topical minoxidil states it has not been studied in pregnant or nursing women and should be used only when clearly needed.

Baricitinib is Category D equivalent (contraindicated in pregnancy) based on animal reproductive toxicology. The FDA prescribing information mandates pregnancy testing before initiation and highly effective contraception during treatment and for at least one week after the last dose.

Hydroxychloroquine used for scarring alopecias is generally considered compatible with pregnancy based on its rheumatology safety record, though this is off-label use for hair. Discuss with your prescriber.

Postpartum telogen effluvium resolves without medication in most women. If treatment is needed, low-level laser therapy (LLLT) devices cleared by the FDA for FPHL carry no known reproductive risk and may be used while breastfeeding, though controlled data in lactating women are absent.

Your Practical Next Steps

Start here regardless of life stage. These four steps apply to every woman presenting with scalp hair loss.

1. Document the timeline. Write down when shedding started and what happened 2-4 months before that. Stress, illness, delivery, diet change, or a new medication starting around that time points strongly to telogen effluvium.
2. Get the core lab panel. TSH, ferritin (not just iron or CBC), free testosterone, DHEA-S, prolactin, and CBC. Ask for ferritin by name and ask for the actual number, not just "normal/abnormal."
3. Photograph your part line monthly. Consistent lighting, same angle. This is your objective data and the single most useful thing you can bring to follow-up visits.
4. See a dermatologist with hair experience or a women's-health specialist if shedding is patchy, if the scalp is symptomatic, or if labs return abnormal and you are not sure of the next step.

A 2022 ACOG Clinical Practice Update notes that hair loss is a clinically significant androgen-excess symptom in PCOS that warrants the same systematic evaluation as hirsutism, a reminder that your gynecologist, not just a dermatologist, is an appropriate first contact.